ArticleScience translational medicine2017
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers.
0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed
15.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
147 citing papers in PubMed, 286 citations in OpenAlex.
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo.The Journal of experimental medicine · 2026Article
- Article
- Article
- Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.Science (New York, N.Y.) · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Clonal dynamics of germinal center refueling by secondary immunization.bioRxiv : the preprint server for biology · 2026Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Germline-somatic residue synergy reshapes antibody encounter-state pathways to enhance HIV-1 recognition.bioRxiv : the preprint server for biology · 2026Article
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities.PLoS computational biology · 2026Article
- Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.Science immunology · 2026Article
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
- The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials.Current HIV research · 2026Review
- Article
- Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.The Journal of experimental medicine · 2025Article
- Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design.bioRxiv : the preprint server for biology · 2025Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 11 institutions in 2 countries.
Mattia BonsignoriDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA. mattia.bonsignori@dm.duke.edu btk@lanl.gov barton.haynes@dm.duke.edu.ORCID 0000-0003-2973-2101
Edward F KreiderDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-2330-8430
Daniela FeraLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1706-9288
R Ryan MeyerhoffDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-1253-2250
Todd BradleyDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-8770-040X
Kevin WieheDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-9933-9618
S Munir AlamDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-0941-0703
Baptiste AussedatDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-8828-8963
William E WalkowiczDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7961-1175
Kwan-Ki HwangDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0002-3903-6997
Kevin O SaundersDuke Human Vaccine Institute, Durham, NC 27710, USA.
Ruijun ZhangDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0002-2342-8232
Morgan A GladdenDuke Human Vaccine Institute, Durham, NC 27710, USA.
Anthony MonroeDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0001-9428-3555
Amit KumarDuke Human Vaccine Institute, Durham, NC 27710, USA.
Shi-Mao XiaDuke Human Vaccine Institute, Durham, NC 27710, USA.
Melissa CooperDuke Human Vaccine Institute, Durham, NC 27710, USA.
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7540-9263
Krisha McKeeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Robert T BailerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Brendan W PierLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Claudia A JetteLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Garnett KelsoeDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0002-8770-040X
Wilton B WilliamsDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2970-7259
Lynn MorrisNational Institute for Communicable Diseases, Johannesburg 2131, South Africa.ORCID 0000-0003-3961-7828
John KappesDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kshitij WaghLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Gift KamangaUniversity of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi.
Myron S CohenDepartments of Medicine, Epidemiology, and Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5917-9664
Peter T HraberLos Alamos National Laboratory, Los Alamos, NM 87545, USA.ORCID 0000-0002-2920-4897
David C MontefioriDuke Human Vaccine Institute, Durham, NC 27710, USA.
Ashley TramaDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0001-7686-0902
Hua-Xin LiaoDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Thomas B KeplerDepartment of Microbiology and Department of Mathematics and Statistics, Boston University, Boston, MA 02215, USA.ORCID 0000-0002-1383-6865
M Anthony MoodyDuke Human Vaccine Institute, Durham, NC 27710, USA.ORCID 0000-0002-3890-5855
Feng GaoDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-8903-0203
Samuel J DanishefskyDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5293-4695
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Beatrice H HahnDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Stephen C HarrisonLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Bette T KorberLos Alamos National Laboratory, Los Alamos, NM 87545, USA. mattia.bonsignori@dm.duke.edu btk@lanl.gov barton.haynes@dm.duke.edu.ORCID 0000-0002-2026-5757
Barton F HaynesDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA. mattia.bonsignori@dm.duke.edu btk@lanl.gov barton.haynes@dm.duke.edu.ORCID 0000-0002-2847-1854
Duke University · USBoston Children's Hospital · USNational Institutes of Health · USLos Alamos National Laboratory · USMemorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · USBoston University · USKamuzu Central Hospital · MWNational Institute for Communicable DiseasesUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kshitij Wagh · 2017 to 2026
$40.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MMeasurement of HIV Neutralization Using Quantitative AssaysZIAAI005010 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$7.6MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MbNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPsR01AI131331 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2017 to 2020
$3.2MInterplay between antibody affinity maturation and HIV evolution in a single hostF32AI116355 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI FERA, DANIELA · 2015 to 2016
$105kNovel mouse model of HIV broad neutralizing antibody inductionF30AI122982 · NIAID · DUKE UNIVERSITY · PI MEYERHOFF, ROBERT RYAN · 2016 to 2017
$79kDiscovery of a Novel Immune Response to the 5' Leader of HIV-1F30AI112426 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KREIDER, EDWARD · 2014 to 2015
$76kNCI NIH HHS P30 CA008748NIAID NIH HHS F30 AI112426NIAID NIH HHS F30 AI122982NIAID NIH HHS F32 AI116355NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI120801NIAID NIH HHS R01 AI131331NIAID NIH HHS UM1 AI100645NIGMS NIH HHS T32 GM007171
Abstract
A preventive HIV-1 vaccine should induce HIV-1-specific broadly neutralizing antibodies (bnAbs). However, bnAbs generally require high levels of somatic hypermutation (SHM) to acquire breadth, and current vaccine strategies have not been successful in inducing bnAbs. Because bnAbs directed against a glycosylated site adjacent to the third variable loop (V3) of the HIV-1 envelope protein require limited SHM, the V3-glycan epitope is an attractive vaccine target. By studying the cooperation among multiple V3-glycan B cell lineages and their coevolution with autologous virus throughout 5 years of infection, we identify key events in the ontogeny of a V3-glycan bnAb. Two autologous neutralizing antibody lineages selected for virus escape mutations and consequently allowed initiation and affinity maturation of a V3-glycan bnAb lineage. The nucleotide substitution required to initiate the bnAb lineage occurred at a low-probability site for activation-induced cytidine deaminase activity. Cooperation of B cell lineages and an improbable mutation critical for bnAb activity defined the necessary events leading to breadth in this V3-glycan bnAb lineage. These findings may, in part, explain why initiation of V3-glycan bnAbs is rare, and suggest an immunization strategy for inducing similar V3-glycan bnAbs.
Indexed as
Antibodies, NeutralizingCrystallography, X-Rayenv Gene Products, Human Immunodeficiency VirusHIV-1HumansMaleMutationNeutralization TestsPhylogenyPolysaccharidesProtein BindingAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusPolysaccharides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.